HIGHLIGHTS
- who: Sae Yumita from the stage, macrovascular invasion, extrahepatic spread, treatment line of Atez/Bev, Eastern Cooperative Oncology Group performance status (ECOG-PS), and neutrophilto-lymphocyte ratio (NLR)This study was approved by the Research Ethics Committee of the Graduate School of Medicine, Chiba University (No., ). Radiological evaluation have published the article: Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice, in the Journal: (JOURNAL)
- what: The aim of this study is to clarify the reality of HPD in patients with advanced hepatocellular carcinoma (HCC) who . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.